26302653 35410469 28494108 29371114 30914442 36584882 26707396 24834870 27523794 33555255 25891774 36179400 24978316 28740600 32949766 24113749 31057409 24187130 27797517 28626043 26635353 30776373 24433041 28088389 28476928 29635340 31463605 2526317 - Search Results

Year	Number of Results
2013	3
2014	11
2015	13
2016	8
2017	9
2018	6
2019	5
2020	5
2021	5
2022	12
2023	3

1

Noribogaine is a G-protein biased κ-opioid receptor agonist.

Maillet EL, Milon N, Heghinian MD, Fishback J, Schürer SC, Garamszegi N, Mash DC. Maillet EL, et al. Neuropharmacology. 2015 Dec;99:675-88. doi: 10.1016/j.neuropharm.2015.08.032. Epub 2015 Aug 21. Neuropharmacology. 2015. PMID: 26302653 Free article.

2

Advances in Sulfonamide Kappa Opioid Receptor Antagonists: Structural Refinement and Evaluation of CNS Clearance.

Ma H, Brust T, Frankowski KJ, Lovell KM, Cameron MD, Bohn LM, Aubé J. Ma H, et al. ACS Chem Neurosci. 2022 Apr 20;13(8):1315-1332. doi: 10.1021/acschemneuro.2c00140. Epub 2022 Apr 11. ACS Chem Neurosci. 2022. PMID: 35410469

3

Selective κ receptor partial agonist HS666 produces potent antinociception without inducing aversion after i.c.v. administration in mice.

Spetea M, Eans SO, Ganno ML, Lantero A, Mairegger M, Toll L, Schmidhammer H, McLaughlin JP. Spetea M, et al. Br J Pharmacol. 2017 Aug;174(15):2444-2456. doi: 10.1111/bph.13854. Epub 2017 Jun 27. Br J Pharmacol. 2017. PMID: 28494108 Free PMC article.

4

A Kappa Opioid Receptor Agonist Blocks Bone Cancer Pain Without Altering Bone Loss, Tumor Size, or Cancer Cell Proliferation in a Mouse Model of Cancer-Induced Bone Pain.

Edwards KA, Havelin JJ, Mcintosh MI, Ciccone HA, Pangilinan K, Imbert I, Largent-Milnes TM, King T, Vanderah TW, Streicher JM. Edwards KA, et al. J Pain. 2018 Jun;19(6):612-625. doi: 10.1016/j.jpain.2018.01.002. Epub 2018 Jan 31. J Pain. 2018. PMID: 29371114

5

Biased Receptor Signaling in Drug Discovery.

Kenakin T. Kenakin T. Pharmacol Rev. 2019 Apr;71(2):267-315. doi: 10.1124/pr.118.016790. Pharmacol Rev. 2019. PMID: 30914442 Review.

6

Key differences in regulation of opioid receptors localized to presynaptic terminals compared to somas: Relevance for novel therapeutics.

Coutens B, Ingram SL. Coutens B, et al. Neuropharmacology. 2023 Mar 15;226:109408. doi: 10.1016/j.neuropharm.2022.109408. Epub 2022 Dec 28. Neuropharmacology. 2023. PMID: 36584882 Free PMC article. Review.

7

Biased agonism: An emerging paradigm in GPCR drug discovery.

Rankovic Z, Brust TF, Bohn LM. Rankovic Z, et al. Bioorg Med Chem Lett. 2016 Jan 15;26(2):241-250. doi: 10.1016/j.bmcl.2015.12.024. Epub 2015 Dec 9. Bioorg Med Chem Lett. 2016. PMID: 26707396 Free PMC article. Review.

8

Biased ligands: pathway validation for novel GPCR therapeutics.

Rominger DH, Cowan CL, Gowen-MacDonald W, Violin JD. Rominger DH, et al. Curr Opin Pharmacol. 2014 Jun;16:108-15. doi: 10.1016/j.coph.2014.04.002. Epub 2014 May 14. Curr Opin Pharmacol. 2014. PMID: 24834870 Review.

9

Heterodimerization of the kappa opioid receptor and neurotensin receptor 1 contributes to a novel β-arrestin-2-biased pathway.

Liu H, Tian Y, Ji B, Lu H, Xin Q, Jiang Y, Ding L, Zhang J, Chen J, Bai B. Liu H, et al. Biochim Biophys Acta. 2016 Nov;1863(11):2719-2738. doi: 10.1016/j.bbamcr.2016.07.009. Epub 2016 Aug 12. Biochim Biophys Acta. 2016. PMID: 27523794 Free article.

10

Controlling opioid receptor functional selectivity by targeting distinct subpockets of the orthosteric site.

Uprety R, Che T, Zaidi SA, Grinnell SG, Varga BR, Faouzi A, Slocum ST, Allaoa A, Varadi A, Nelson M, Bernhard SM, Kulko E, Le Rouzic V, Eans SO, Simons CA, Hunkele A, Subrath J, Pan YX, Javitch JA, McLaughlin JP, Roth BL, Pasternak GW, Katritch V, Majumdar S. Uprety R, et al. Elife. 2021 Feb 8;10:e56519. doi: 10.7554/eLife.56519. Elife. 2021. PMID: 33555255 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results